Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients

Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery

“…Published literature also reports lower than recommended use of thromboprophylaxis after discharge following hipand knee-replacement surgery; however, the determinants of this low use are not well understood. 6,[20][21][22][23][24][25] In our study, patients who received hip-or knee-replacement surgery at a teaching hospital were less likely than those who received surgery at a community hospital to receive thromboprophylaxis after discharge, and those with higher income were more likely to receive these medications after discharge. These findings require further investigation to assess whether they reflect differences in physician behaviour or health status between patients with higher and lower incomes and differences between patients at teaching and community hospitals.…”

VKORC1 Variant Genotypes Influence Warfarin Response in Patients Undergoing Total Joint Arthroplasty: A Pilot Study

“…A survey of the members of the American Association of Hip and Knee Surgeons in 2001 revealed warfarin was the most frequent form of pharmacologic thromboprophylaxis used at that time in 66% of THAs and 59% of TKAs [22]. Large individual dosage variations of warfarin are required to achieve prophylactic and therapeutic ranges.…”

Compliance of dutch orthopedic departments with national guidelines on thromboprophylaxis

“…Several studies investigating practice regarding orthopedic thromboprophylaxis have been published from the United States (Mesko et al 2001), Canada (Gross et al 1999), the UK (Francis and Brenkel 1997), Sweden (Bergqvist 1985), and Australia and New Zealand (Rodgers et al 1994). A wide variation in regimens is common in all these studies; unfortunately, it is not known how this reflects on the incidence of VTE.…”